President Donald Trump’s head of the Food and Drug Administration (FDA) Dr. Martin A. “Marty” Makary announced major policy changes on Thursday at the agency and said they will no longer allow pharma members to be part of FDA advisory panels, removing further conflicts of interest.
During the Sirius XM “The Megyn Kelly Show” podcast, Kelly pointed out that almost every former FDA commissioner has left the agency and gone into “Big Pharma,” which she said makes it harder to count on them to be honest about a drug’s impact.
The newly-confirmed FDA Commissioner agreed, and said the “scientific evaluation” of drugs needs to be independent.
“That’s why today we are announcing we’re removing industry members, pharma members, from FDA advisory committees,” Makary said. “I was shocked when I learned that employees of big pharma…
